Finding safer drug combinations for treating relapsed sarcoma in children
Identifying non-cardiotoxic drug combinations for patients with relapsed sarcoma
['FUNDING_R21'] · SEATTLE CHILDREN'S HOSPITAL · NIH-11037898
This study is looking for safe drug combinations to help treat children with relapsed sarcoma while making sure they don’t harm the heart, using special models to test the treatments before trying them in kids.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SEATTLE CHILDREN'S HOSPITAL (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11037898 on ClinicalTrials.gov |
What this research studies
This research aims to identify drug combinations that can effectively treat relapsed sarcoma in children without causing heart damage. By using advanced models, including mouse xenografts and zebrafish, the team will evaluate the cardiotoxic effects of these combinations before they are tested in patients. The goal is to develop safer treatment options that minimize the risk of heart complications while still targeting the cancer effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults with relapsed sarcoma who are at risk of cardiotoxicity from standard treatments.
Not a fit: Patients with sarcoma who are not experiencing relapse or those who are not at risk for cardiotoxicity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer treatment options for children with relapsed sarcoma, reducing the risk of heart damage associated with current therapies.
How similar studies have performed: Other research has shown promise in developing safer cancer therapies, but this specific approach combining zebrafish and mouse models for cardiotoxicity assessment is relatively novel.
Where this research is happening
SEATTLE, UNITED STATES
- SEATTLE CHILDREN'S HOSPITAL — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LAWLOR, ELIZABETH R — SEATTLE CHILDREN'S HOSPITAL
- Study coordinator: LAWLOR, ELIZABETH R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug